{"id":"ketotifen-fumarate-0-035","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Conjunctival injection"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Dry eye"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ketotifen works through dual action: it competitively blocks H1 histamine receptors to prevent histamine-mediated allergic symptoms, and it stabilizes mast cells to reduce the release of inflammatory mediators including histamine, tryptase, and leukotrienes. This combination makes it particularly effective for allergic conditions affecting the eye.","oneSentence":"Ketotifen is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic reactions by blocking histamine release and reducing mast cell degranulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:59.049Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic conjunctivitis"},{"name":"Itching associated with allergic conditions of the eye"}]},"trialDetails":[{"nctId":"NCT05815758","phase":"PHASE3","title":"Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2023-04-20","conditions":"Allergic Conjunctivitis","enrollment":512},{"nctId":"NCT05591755","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-11-18","conditions":"Seasonal Allergic Conjunctivitis","enrollment":229},{"nctId":"NCT05579730","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-10-12","conditions":"Allergic Conjunctivitis","enrollment":188},{"nctId":"NCT03489941","phase":"PHASE3","title":"A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2018-04-07","conditions":"Allergic Conjunctivitis","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ketotifen Fumarate 0.035%","genericName":"Ketotifen Fumarate 0.035%","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ketotifen is a selective H1-receptor antagonist and mast cell stabilizer that prevents allergic reactions by blocking histamine release and reducing mast cell degranulation. Used for Allergic conjunctivitis, Itching associated with allergic conditions of the eye.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}